Drugs / Modified Process Hepatitis B Vaccine
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT00322361 | May 2006 → Jul 2007 | hepatitis B virus infection, hepatocellular carcinoma | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 34 trials · 2 missed | ||||||
| Phase 3 | NCT00440297 | Dec 2006 → May 2008 | hepatitis B virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00440531 | Nov 2006 → Nov 2007 | hepatitis B virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00414050 | Oct 2006 → Oct 2007 | hepatitis B virus infection | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 3 | NCT00393523 | Sep 2006 → Jun 2008 | hepatitis B virus infection | Merck Sharp & Dohme LLC | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Modified Process Hepatitis B Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00440531 ↗ |
| Known as | mpHBV | “This study examined the immune response engendered in older adults by RECOMBIVAX HB™ manufactured using a modified adjuvant (modified-process hepatitis B vaccine; mpHBV),...” PMID 22185811 ↗ Dec 20113“This modified process hepatitis B vaccine (mpHBV), which was previously shown to have an acceptable safety and immunogenicity profile in young adults, has now been studied in...” PMID 22227229 ↗ Jan 2012 “A modified process hepatitis B vaccine (mpHBV) uses higher phosphate content in the manufacturing process relative to the current product, Recombivax-HB.” PMID 21552183 ↗ Jul 2011 “A manufacturing process modification for a hepatitis B vaccine (mpHBV) was studied in renal pre-dialysis and dialysis patients.” PMID 25252192 ↗ Sep 2014 |
| Modality | Vaccine | “modified process hepatitis B vaccine” NCT00322361 ↗ |
| Route | Intramuscular | “administered via intramuscular injection” NCT00322361 ↗ |